Protagonist Therapeutics reported second-quarter financial results that marked a dramatic turnaround from a year-earlier loss. The company posted a profit of $162.8 million, or $2.29 per diluted share, compared with a $34.8 million loss in the same period the previous year. The improvement was driven primarily by milestone payments tied to two therapeutic candidates advancing toward or achieving commercial availability.
ICOTYDE received FDA approval on March 18 for treating moderate-to-severe plaque psoriasis in patients aged 12 and older weighing at least 40 kilograms. The approval triggered a $50 million milestone payment and represented the first and only FDA-approved targeted oral peptide for the condition, according to the company. Through its partnership with Johnson & Johnson, Protagonist can collect up to an additional $580 million in milestone payments and royalties averaging approximately 7.25 percent at $4 billion in annual sales.
Rusfertide, an injectable treatment for polycythemia vera, carries additional financial potential. The drug’s new drug application was under Priority Review with an FDA decision target date in August. Partner Takeda had already paid Protagonist $200 million related to an opt-out election in April, with another $200 million and a $75 million approval milestone pending, plus potential royalties reaching 29 percent of sales exceeding $1.5 billion. A third program, PN-881, is slated to begin a Phase 2b psoriasis trial in early 2027, while PN-477sc, an injectable obesity peptide, recently initiated Phase 1 testing.
However, analysts noted that a significant portion of reported revenue derived from deal payments rather than direct product sales. Of the $213.5 million in license and collaboration revenue, $192.4 million came from recognizing Takeda’s initial payment rather than repeatable commercial sales. Management also signaled that research and development expenses would rise substantially during the second half of the year, alongside increases in general and administrative costs driven by stock-based compensation.
The company’s financial position reflected other market dynamics as well. Cash and marketable securities reached $849.5 million. Hedge fund ownership increased slightly from 42 to 43 funds, while short interest remained elevated at 13.99 percent of the float. The stock traded at a forward price-to-earnings ratio of 36.90 as of September 4, suggesting the market was pricing in substantial future earnings growth while maintaining significant uncertainty about the company’s trajectory.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI